VIGL — Vigil Neuroscience Share Price
Last trade - 00:00- $150.34m
- $48.69m
- 22
- 26
- 25
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 1.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.85% | ||
| Return on Equity | -60.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.29 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Directors
- Bruce Booth CHM (47)
- Ivana Magovcevic-Liebisch PRE
- Jennifer Ziolkowski CFO
- Evan Thackaberry SVP
- Spyros Papapetropoulos EXO
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 22nd, 2020
- Public Since
- January 7th, 2022
- No. of Shareholders
- 12
- No. of Employees
- 65
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 37,584,312
- Address
- 100 Forge Road, Suite 700, WATERTOWN, 02472
- Web
- https://www.vigilneuro.com/
- Phone
- +1 8572544445
- Auditors
- PricewaterhouseCoopers LLP
Similar to VIGL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 24:02 UTC, shares in Vigil Neuroscience are trading at $3.86. This share price information is delayed by 15 minutes.
Shares in Vigil Neuroscience last closed at $3.86 and the price had moved by -61.4% over the past 365 days. In terms of relative price strength the Vigil Neuroscience share price has underperformed the S&P500 Index by -69.29% over the past year.
The overall consensus recommendation for Vigil Neuroscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Vigil Neuroscience does not currently pay a dividend.
Vigil Neuroscience does not currently pay a dividend.
Vigil Neuroscience does not currently pay a dividend.
To buy shares in Vigil Neuroscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.86, shares in Vigil Neuroscience had a market capitalisation of $145.08m.
Here are the trading details for Vigil Neuroscience:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VIGL
Based on an overall assessment of its quality, value and momentum Vigil Neuroscience is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Vigil Neuroscience is $16.75. That is 333.94% above the last closing price of $3.86.
Analysts covering Vigil Neuroscience currently have a consensus Earnings Per Share (EPS) forecast of -$1.92 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vigil Neuroscience. Over the past six months, its share price has underperformed the S&P500 Index by -8.85%.
As of the last closing price of $3.86, shares in Vigil Neuroscience were trading -5.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vigil Neuroscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vigil Neuroscience's management team is headed by:
- Bruce Booth - CHM
- Ivana Magovcevic-Liebisch - PRE
- Jennifer Ziolkowski - CFO
- Evan Thackaberry - SVP
- Spyros Papapetropoulos - EXO